Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The RECOVERY trial has been named David Sackett Trial of the Year by the Society for Clinical Trials. The award was presented today at the Society for Clinical Trials’ 42nd Annual Meeting.

Logo of the Society for Clinical Trials

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is a large, pragmatic randomised trial for the treatment of hospitalised patients with suspected or confirmed COVID-19. It was designed and implemented at extraordinary speed in the midst of the COVID-19 pandemic, at a time of great need for effective treatments to reduce mortality among hospitalised patients.

Peter Horby, Professor of Emerging Infectious Diseases in the Nuffield Department of Medicine, University of Oxford, and Joint Chief Investigator for the RECOVERY trial, said ‘This award is a testament and a tribute to the exceptional work of many thousands of people working under the most difficult circumstances. 2020 was awful in so many ways but the RECOVERY trial was uplifting, showing what can be achieved when there is unity, resolve and a commitment to good science. RECOVERY is a truly national achievement and every person involved should feel incredibly proud. I would encourage them to regularly remind themselves that there are many thousands of people who are only alive today thanks to their efforts.’ 

Every year since 2008, the Society for Clinical Trials has awarded the David Sackett Trial of the Year Award to a randomised, controlled trial published in the previous calendar year that best fulfills the following standards: improves the lot of humankind; provides the basis for a substantial, beneficial change in health care; reflects expertise in subject matter, excellence in methodology, and concern for study participants; overcomes obstacles in implementation; and based on the presentation of its design, execution, and results is a model of clarity and intellectual soundness.

The full story is available on the RECOVERY website

Similar stories

RECOVERY trial team members appointed MBEs

Two RECOVERY Trial team members have been recognised in the New Year Honours list 2022. RECOVERY Trial coordinator, Professor Richard Haynes, has been appointed Member of the Order of the British Empire (MBE) for services to Global Health, and Senior Clinical Trial Manager, Lucy Fletcher, has been appointed MBE for services to Clinical Trials. The New Year Honours list recognises outstanding achievements by a wide range of extraordinary people from across the United Kingdom. People are awarded honours for achievements in their field of work (including health, education, science and technology), as well as for making a difference to their community.

Susie, Phaik Yeong, Richard and Paul among new full Oxford professors!

In the 2021 Oxford Recognition of Distinction round, four MORU colleagues were awarded Full Professor title.

RECOVERY Trial launches in South Africa

The world’s largest clinical trial investigating treatments for COVID-19 has now launched in South Africa, with the first patient recruited today. This is the fifth country to take part in RECOVERY, joining Nepal, Indonesia, Vietnam, and the United Kingdom.

RECOVERY Trial wins ‘Oscar of Higher Education’ for STEM Research Project of the year

The RECOVERY Trial has been awarded the 2021 Times Higher Education (THE) Award in the ‘Research Project of the Year: STEM’ category.

Antibiotic accountability: how countries and companies perform

Patients in north Africa and the Middle East are using antibiotics in sharply rising quantities far beyond the global average, raising concerns over the escalating risks of resistance to medicines to treat bacterial infections. Estimated antibiotic consumption for 204 countries between 2000 and 2018 shows a 46 per cent increase in global antibiotic usage, with a surge in nations including India and Vietnam.

Paul Newton named ASTMH Distinguished International Fellow

Professor Paul Newton was announced new Distinguished International Fellow at the ASTMH Annual Meeting Awards Ceremony on the 17th November. This distinction formally recognizes individuals who have made eminent contributions to a particular aspect of tropical medicine or hygiene.